{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:16:21Z","timestamp":1777637781859,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clml.2024.02.012","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T19:14:57Z","timestamp":1708715697000},"page":"e267-e275.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"given":"Ludek","family":"Pour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilina","family":"Micheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganna","family":"Usenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-7398","authenticated-orcid":false,"given":"Gabor","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kameliya","family":"Simeonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5431-9365","authenticated-orcid":false,"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunilla","family":"Huledal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-9900","authenticated-orcid":false,"given":"Stefan","family":"Norin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaas A.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-326X","authenticated-orcid":false,"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.02.012_bib0001","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.02.012_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2024.02.012_bib0003","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.02.012_bib0004","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/17512433.2022.2075847","article-title":"Melflufen for the treatment of multiple myeloma","volume":"15","author":"Ocio","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clml.2024.02.012_bib0005","doi-asserted-by":"crossref","first-page":"66641","DOI":"10.18632\/oncotarget.18420","article-title":"Melflufen - a peptidase-potentiated alkylating agent in clinical trials","volume":"8","author":"Wickstr\u00f6m","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2024.02.012_bib0006","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","article-title":"In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells","volume":"19","author":"Chauhan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2024.02.012_bib0007","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1\u20132 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.02.012_bib0008","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.02.012_bib0009","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.02.012_bib0010","unstructured":"Pepaxti (melphalan flufenamide) Injection [Summary of Product Characteristics]: Stockholm, Sweden: Oncopeptides AB; 2023."},{"key":"10.1016\/j.clml.2024.02.012_bib0011","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.sla.0000171874.29934.61","article-title":"Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial","volume":"242","author":"Darouiche","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.clml.2024.02.012_bib0012","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMra011883","article-title":"Preventing complications of central venous catheterization","volume":"348","author":"McGee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.02.012_bib0013","first-page":"e4717","article-title":"Central line catheters and associated complications: A review","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.clml.2024.02.012_bib0014","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/JCO.2012.45.5733","article-title":"Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Schiffer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.02.012_bib0015","unstructured":"Bendeka\u00ae (bendamustine hydrochloride) Injection [prescribing information]: Parsippany, NJ: Teva Pharmaceuticals; 2024."},{"key":"10.1016\/j.clml.2024.02.012_bib0016","unstructured":"Cyclophosphamide Injection [prescribing information]: Deerfield, IL: Baxter Healthcare Corporation; 2017."},{"key":"10.1016\/j.clml.2024.02.012_bib0017","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0277-5379(86)90005-2","article-title":"Peptichemio in pretreated patients with plasmacell neoplasms","volume":"22","author":"Paccagnella","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.clml.2024.02.012_bib0018","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.02.012_bib0019","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jcph.2355","article-title":"Pharmacokinetics and metabolism of melflufen, an alkylating peptide-drug conjugate, in patients with relapsed refractory multiple myeloma","volume":"64","author":"Huledal","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clml.2024.02.012_bib0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00129804-200611000-00004","article-title":"Evaluation of a visual infusion phlebitis scale for determining appropriate discontinuation of peripheral intravenous catheters","volume":"29","author":"Gallant","year":"2006","journal-title":"J Infus Nurs"},{"key":"10.1016\/j.clml.2024.02.012_bib0021","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.02.012_bib0022","unstructured":"Oncopeptides. Press Release, 2023. Available at: https:\/\/www.oncopeptides.com\/en\/media\/press-releases\/updated-results-from-phase-3-ocean-study-shows-melflufen-met-primary-endpoint-of-superior-pfs-overall-survival-data-lead-to-partial-clinical-hold. Accessed: September 18, 2023."},{"key":"10.1016\/j.clml.2024.02.012_bib0023","unstructured":"US Food and Drug Administration. FDA drug alert, 2023. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-alerts-patients-and-health-care-professionals-about-clinical-trial-results-showing-increased. Accessed: September 18, 2023."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T13:03:00Z","timestamp":1716987780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2152265024000910"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}